Steven W. Ressler MD

Dr. Steven W. Ressler MD

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2017 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
MPMichael Pham
Michael Pham
SMSteven W. Ressler MD
Steven W. Ressler MD
ARAllison Rosenthal
Allison Rosenthal
KKKatalin Kelemen
Katalin Kelemen
Hodgkin lymphoma is a hematologic malignancy usually confined to lymphatic structures and commonly associated with constitutional symptoms. Bony involvement and musculoskeletal symptoms are uncommon and typically seen in advanced disease. In this case, we report an unusual presentation of classical Hodgkin lymphoma and highlight diagnostic challenges leading to the misdiagnosis and treatment as chronic recurrent multifocal osteomyelitis. A 38-year-old white man presented with lower extremity musculoskeletal pain. Imaging studies revealed multifocal lytic and sclerotic osseous axial lesions. Multiple core needle bone marrow and excisional lymph node biopsies were non-diagnostic. Having met the criteria, a tentative diagnosis of chronic recurrent multifocal osteomyelitis was given. He was treated with non-steroidal anti-inflammatory medications with partial clinical response but had persistent symptoms. A second medical opinion was pursued. An open bone marrow biopsy was performed and yielded a diagnosis of classical Hodgkin lymphoma after 13 months of diagnostic uncertainty. A chemotherapy regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine was instituted with complete symptomatic and radiologic response. This case illustrates diagnostic difficulties of a musculoskeletal presentation of Hodgkin lymphoma, challenges of non-diagnostic bone marrow and lymph node biopsies, and resultant diagnostic delays in delivering a potentially curative therapy. Had the additional open bone marrow biopsy not been performed, the diagnosis and treatment of Hodgkin lymphoma would have been missed.

31 March 2012 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
KBKathryn B. Bollin
Kathryn B. Bollin
MKMeaghan L. Khan
Meaghan L. Khan
SMSteven W. Ressler MD
Steven W. Ressler MD

13 March 2025 in Journal of Primary Care & Community Health
Verified
Journal Article
Open access
SMSteven W. Ressler MD
Steven W. Ressler MD
ICIvana Croghan
Ivana Croghan
MGMarlene E. Girardo
Marlene E. Girardo
JFJohn P. Fasolino
John P. Fasolino
EGElizabeth A. Gilman
Elizabeth A. Gilman
KGKarthik Ghosh
Karthik Ghosh
Introduction: The Undiagnosed Mass Clinic (UMC) at our institution is a clinical and research program created to address gaps in the early diagnostic phase of the cancer care continuum for patients with potential malignant neoplasms. All patients referred to the UMC are invited to participate in the UMC registry, which tracks operational and clinical metrics while maintaining a repository of blood and tissue specimens for future research. Methods: We conducted a retrospective cohort study of the first 100 patients enrolled in the UMC registry. We analyzed patient demographics, final diagnoses, and the time from initial consultation to final diagnosis. Results: Most participants were White (86%), non-Hispanic (93%), and married (72%). The mean (SD) age was 64 (13.9) years. The final diagnoses of the masses were categorized as malignant/neoplastic with malignant potential (n = 53), benign (n = 36), or requiring diagnostic surveillance (n = 10). The mean (SD) time from initial consultation to final diagnosis of malignant/neoplastic with malignant potential masses significantly improved from 37.4 (36.6) days for the first 50 participants to 17.3 (19.7) days for the next 50 participants ( P = .006). Conclusions: These initial insights from the UMC registry will help direct future efforts to improve the care of patients with potential malignant neoplasms.

28 September 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
JAJessica Danielle Austin
Jessica Danielle Austin
Ilyse Arielle NelsonIlyse Arielle Nelson
Ilyse Arielle Nelson
JTJon C. Tilburt
Jon C. Tilburt
EEEric Ellinghysen
Eric Ellinghysen
CYClaire Ida Yee
Claire Ida Yee
SMSteven W. Ressler MD
Steven W. Ressler MD
Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.

1 September 2026 in Cancer Prevention Research
Verified
Journal Article
Closed access
AWAlexandra Wicker
Alexandra Wicker
ACAmanda Courtright-Lim
Amanda Courtright-Lim
LRLila J. Jean Finney Rutten
Lila J. Jean Finney Rutten
SMSteven W. Ressler MD
Steven W. Ressler MD
JTJon C. Tilburt
Jon C. Tilburt
JAJessica Danielle Austin
Jessica Danielle Austin
As technological and genomic innovations continue to advance precision cancer prevention, psychosocial, ethical, and operational complexities increasingly accompany their development. Addressing these challenges will require intentional cross-disciplinary collaboration. We argue that the distinct yet complementary lenses of bioethics and implementation science will be crucial as precision cancer prevention technologies move toward clinical integration. We provide a framework for how this joint effort can be accomplished and sustained across the translational pipeline.